Collagen–Chitosan Composite Hemostatic Materials
Composite Biomaterial · Rapid Fluid Uptake · Porous Architecture · Structural Integrity
A composite biomaterial development platform combining collagen and chitosan to explore rapid fluid uptake, scaffold performance and improved structural integrity. From formulation and scaffold optimization to lyophilization, testing and OEM manufacturing.
Composite Biomaterial
Rapid Fluid Uptake
Porous Architecture
Structural Integrity
Why Composite Biomaterials
Single-component biomaterial platforms have defined material property boundaries. Composite biomaterial development explores how combining two or more components — in this case collagen and chitosan — can expand the achievable range of scaffold properties. The collagen–chitosan platform is developed as a next-generation approach to porous hemostatic biomaterial engineering.
Collagen–Chitosan Platform
The platform combines a collagen matrix with a chitosan component. Collagen provides the primary scaffold structure and biological surface chemistry. Chitosan contributes structural characteristics, fluid interaction properties and potential for additional material functionality. The ratio, molecular weight and processing parameters of each component are development variables that influence the final scaffold properties.
Porous Structure Development
Porous scaffold architecture in the collagen–chitosan composite is controlled through formulation parameters and the lyophilization process. Pore size distribution, interconnectivity and overall scaffold geometry are characterized for each development batch. Scaffold architecture optimization is a core part of the development process.
Fluid Uptake
Fluid uptake is a key functional parameter for hemostatic biomaterials. The collagen–chitosan composite platform is developed to explore rapid fluid uptake through scaffold architecture and material surface chemistry. Fluid uptake is measured and documented during prototype development and material characterization.
Mechanical & Structural Integrity
The addition of chitosan to the collagen matrix is explored as a means of improving scaffold structural integrity. Mechanical properties including compressive strength and handling characteristics are evaluated during prototype development. Structural integrity under wet conditions is a specific focus of the composite platform development.
Freeze-Drying Optimization
Lyophilization process parameters — including freezing rate, shelf temperature profile and primary and secondary drying conditions — are optimized for the collagen–chitosan composite formulation. The composite system requires specific process development to achieve consistent scaffold architecture and material properties.
Prototype & Testing
Prototype development follows a defined cycle: formulation, casting, controlled freezing, lyophilization and characterization. Testing includes scaffold structure analysis, fluid uptake measurement, porosity characterization, mechanical property evaluation and batch documentation. Iterative development cycles allow systematic optimization.
OEM & Custom Development
ShiLai™ supports qualified B2B partners with custom development of collagen–chitosan composite hemostatic biomaterials. Custom composition ratios, dimensions, porosity parameters and packaging can be discussed. Scale-up from prototype to production is supported through our manufacturing platform.
Frequently Asked Questions
What is a collagen–chitosan composite hemostatic material?
A collagen–chitosan composite hemostatic material combines a collagen matrix with a chitosan component to create a porous biomaterial scaffold. The composite structure is developed to explore enhanced fluid uptake, scaffold performance and structural integrity.
Why combine collagen and chitosan in a hemostatic biomaterial?
Combining collagen and chitosan allows exploration of complementary material properties. Chitosan contributes structural characteristics and fluid interaction properties that can be tuned alongside the collagen matrix to optimize scaffold performance.
Can ShiLai™ develop custom collagen–chitosan hemostatic materials for OEM partners?
Yes. ShiLai™ supports qualified B2B partners with custom development of collagen–chitosan composite hemostatic biomaterials, including formulation, scaffold optimization, lyophilization, testing and scale-up manufacturing.
Is this product FDA cleared or CE marked?
ShiLai™ does not claim FDA clearance, CE marking or clinical validation for this development-stage platform unless specifically documented. Regulatory requirements depend on the intended application and destination market.